BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 10967572)

  • 1. Bleeding risk and platelet transfusion refractoriness in patients with acute myelogenous leukemia who undergo autologous stem cell transplantation.
    Toor AA; Choo SY; Little JA
    Bone Marrow Transplant; 2000 Aug; 26(3):315-20. PubMed ID: 10967572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloimmune platelet transfusion refractoriness circumvented by allogeneic stem cell transplantation.
    Bonstein L; Stemer G; Dann EJ; Zuckerman T; Fineman R; Haddad N
    Transfusion; 2013 May; 53(5):1019-23. PubMed ID: 22897696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia.
    Moore J; Nivison-Smith I; Goh K; Ma D; Bradstock K; Szer J; Durrant S; Schwarer A; Bardy P; Herrmann R; Dodds A
    Biol Blood Marrow Transplant; 2007 May; 13(5):601-7. PubMed ID: 17448920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
    Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Platelet alloimmunization in patients with oncologic blood disorders treated with multiple transfusions: prospective study in adults and children].
    Pereira J; Bronfman L; Bertín P; Marzouka E; Hidalgo P; Amaya S; Mezzano D
    Rev Med Chil; 1997 Nov; 125(11):1305-12. PubMed ID: 9609051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
    Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission.
    Lee SH; Lee MH; Lee JH; Min YH; Lee KH; Cheong JW; Lee J; Park KW; Kang JH; Kim K; Kim WS; Jung CW; Choi SJ; Lee JH; Park K
    Biol Blood Marrow Transplant; 2005 Feb; 11(2):122-8. PubMed ID: 15682073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The platelet-refractory bone marrow transplant patient: prophylaxis and treatment of bleeding.
    Benson K; Fields K; Hiemenz J; Zorsky P; Ballester O; Perkins J; Elfenbein G
    Semin Oncol; 1993 Oct; 20(5 Suppl 6):102-9. PubMed ID: 8211211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Similar survival following HLA-identical sibling transplantation for standard indication in children with haematologic malignancies: a single center comparison of mobilized peripheral blood stem cell with bone marrow transplantation.
    Meisel R; Enczmann J; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Wernet P; Göbel U; Laws HJ; Dilloo D
    Klin Padiatr; 2005; 217(3):135-41. PubMed ID: 15858704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party.
    Schmid C; Labopin M; Nagler A; Bornhäuser M; Finke J; Fassas A; Volin L; Gürman G; Maertens J; Bordigoni P; Holler E; Ehninger G; Polge E; Gorin NC; Kolb HJ; Rocha V;
    J Clin Oncol; 2007 Nov; 25(31):4938-45. PubMed ID: 17909197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation.
    Gurkan E; Patah PA; Saliba RM; Ramos CA; Anderson BS; Champlin R; de Lima M; Lichtiger B
    Bone Marrow Transplant; 2007 Sep; 40(5):461-4. PubMed ID: 17589530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
    Schmid C; Schleuning M; Ledderose G; Tischer J; Kolb HJ
    J Clin Oncol; 2005 Aug; 23(24):5675-87. PubMed ID: 16110027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute myeloid leukemia from diagnosis to bone marrow transplantation: experience from a single centre.
    Gamberi B; Bandini G; Visani G; Rosti G; Cenacchi A; Motta MR; Fruet F; Calori E; Rizzi S; Tosi P
    Bone Marrow Transplant; 1994 Jul; 14(1):69-72. PubMed ID: 7951122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience.
    Arellano ML; Langston A; Winton E; Flowers CR; Waller EK
    Biol Blood Marrow Transplant; 2007 Jan; 13(1):116-23. PubMed ID: 17222760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alloimmunization following platelet transfusions in patients with acute nonlymphocytic leukemia.
    Nozaki H; Shimizu M; Komatsuda M; Watanabe K; Nagao T; Arimori S
    Tokai J Exp Clin Med; 1986 Aug; 11(3):201-4. PubMed ID: 3475819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Donor peripheral stem cells infusion for the treatment of failure of platelet recovery after allogeneic hematopoietic stem cell transplantation].
    Chen Y; Xu LP; Liu DH; Chen YH; Han W; Shi HX; Zhang XH; Wang JZ; Chen H; Liu KY; Huang XJ; Lu DP
    Zhonghua Yi Xue Za Zhi; 2007 Apr; 87(14):964-6. PubMed ID: 17650420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Emergence of donor-derived anti-HLA antibody and subsequent transfusion-refractory thrombocytopenia after allogeneic hematopoietic stem cell transplantation from an HLA-matched sibling donor in a patient with acute myeloid leukemia].
    Uchiyama Y; Hoshino T; Mihara M; Mitsui T; Koiso H; Takizawa M; Yokohama A; Saitoh T; Uchiumi H; Handa H; Tsukamoto N; Murakami H; Nojima Y
    Rinsho Ketsueki; 2013 Feb; 54(2):214-8. PubMed ID: 23470830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation.
    Wandt H; Schaefer-Eckart K; Frank M; Birkmann J; Wilhelm M
    Bone Marrow Transplant; 2006 Feb; 37(4):387-92. PubMed ID: 16400342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Platelet transfusion refractoriness and effective management of platelet alloimmunization].
    Amemiya Y
    Nihon Rinsho; 1997 Sep; 55(9):2392-8. PubMed ID: 9301306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.